International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2026
Efficacy and safety of contezolid-containing treatment in treating Gram-positive bacterial bloodstream infections following cardiac surgery: A single-center real-world experience.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Wang Yan, Chen Yong, Li Fei, Zhou Peixi, Lei Jinghan, Cui Shunyao, Ye Xiaofang, Wu Yuanxing
Аннотация
OBJECTIVES: This study aimed to evaluate the real-world feasibility of contezolid-containing treatment in patients with Gram-positive bacterial bloodstream infections (GPB-BSIs) following cardiac surgery.
METHODS: A single-center retrospective analysis was conducted, including 22 patients with post-cardiac surgery GPB-BSIs who received contezolid treatment. The primary outcome was the overall clinical response rate.
RESULTS: The overall clinical response rate of contezolid-containing treatment was 77.3% (17/22, 95% CI: 54.6-92.2%), with 9 patients achieving cure and 8 achieving improvement. The microbial eradication rate reached 92.6% (25/27, 95% CI: 75.0-99.1%), particularly 95% (19/20, 95% CI: 75.3-99.9%) for coagulase-negative staphylococci (CoNS)-the dominant pathogen. The overall adverse event (AE) incidence was 9.1% (2/22, 95% CI: 1.1-29.2%), involving two Grade II renal injury events with low correlation to contezolid. No cases of new-onset or exacerbated thrombocytopenia were observed, and no patients discontinued treatment due to AEs. The in-hospital mortality was 4.5% (1/22), with median total hospital stay and ICU stay of 31.0 (interquartile range[IQR]: 25.0-45.5) days and 11.0 (IQR: 8.0-16.0) days, respectively.
CONCLUSION: This study reports the initial clinical experience with contezolid-containing regimens for GPB-BSIs in a complex post-cardiac surgery cohort, supporting its feasibility in this population. These descriptive findings highlight the need for prospective studies to further evaluate its role.
METHODS: A single-center retrospective analysis was conducted, including 22 patients with post-cardiac surgery GPB-BSIs who received contezolid treatment. The primary outcome was the overall clinical response rate.
RESULTS: The overall clinical response rate of contezolid-containing treatment was 77.3% (17/22, 95% CI: 54.6-92.2%), with 9 patients achieving cure and 8 achieving improvement. The microbial eradication rate reached 92.6% (25/27, 95% CI: 75.0-99.1%), particularly 95% (19/20, 95% CI: 75.3-99.9%) for coagulase-negative staphylococci (CoNS)-the dominant pathogen. The overall adverse event (AE) incidence was 9.1% (2/22, 95% CI: 1.1-29.2%), involving two Grade II renal injury events with low correlation to contezolid. No cases of new-onset or exacerbated thrombocytopenia were observed, and no patients discontinued treatment due to AEs. The in-hospital mortality was 4.5% (1/22), with median total hospital stay and ICU stay of 31.0 (interquartile range[IQR]: 25.0-45.5) days and 11.0 (IQR: 8.0-16.0) days, respectively.
CONCLUSION: This study reports the initial clinical experience with contezolid-containing regimens for GPB-BSIs in a complex post-cardiac surgery cohort, supporting its feasibility in this population. These descriptive findings highlight the need for prospective studies to further evaluate its role.